BAUSCH AND LOMB INC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAUSCH AND LOMB INC, and when can generic versions of BAUSCH AND LOMB INC drugs launch?
BAUSCH AND LOMB INC has twenty approved drugs.
There are thirty-two US patents protecting BAUSCH AND LOMB INC drugs.
There are three hundred and seventy-nine patent family members on BAUSCH AND LOMB INC drugs in thirty-one countries and forty-three supplementary protection certificates in fourteen countries.
Summary for BAUSCH AND LOMB INC
| International Patents: | 379 |
| US Patents: | 32 |
| Tradenames: | 20 |
| Ingredients: | 15 |
| NDAs: | 20 |
| Drug Master File Entries: | 1 |
Drugs and US Patents for BAUSCH AND LOMB INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | XIPERE | triamcinolone acetonide | SUSPENSION;INJECTION | 211950-001 | Oct 22, 2021 | RX | Yes | Yes | 9,636,332 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Bausch And Lomb Inc | METHAZOLAMIDE | methazolamide | TABLET;ORAL | 207438-002 | Oct 5, 2018 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | AB | RX | Yes | Yes | 8,084,047 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | AB | RX | Yes | Yes | 8,592,450 | ⤷ Subscribe | ⤷ Subscribe | |||
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | AB | RX | Yes | Yes | 7,745,460 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |
| Bausch And Lomb Inc | XIPERE | triamcinolone acetonide | SUSPENSION;INJECTION | 211950-001 | Oct 22, 2021 | RX | Yes | Yes | 8,636,713 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Bausch And Lomb Inc | TIMOPTIC IN OCUDOSE | timolol maleate | SOLUTION/DROPS;OPHTHALMIC | 019463-002 | Nov 5, 1986 | AT3 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BAUSCH AND LOMB INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | 10,124,000 | ⤷ Subscribe |
| Bausch And Lomb Inc | TIMOPTIC-XE | timolol maleate | SOLUTION, GEL FORMING/DROPS;OPHTHALMIC | 020330-001 | Nov 4, 1993 | 4,861,760 | ⤷ Subscribe |
| Bausch And Lomb Inc | TIMOPTIC | timolol maleate | SOLUTION/DROPS;OPHTHALMIC | 018086-002 | Approved Prior to Jan 1, 1982 | 3,655,663 | ⤷ Subscribe |
| Bausch And Lomb Inc | TIMOPTIC IN OCUDOSE | timolol maleate | SOLUTION/DROPS;OPHTHALMIC | 019463-002 | Nov 5, 1986 | 4,195,085 | ⤷ Subscribe |
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | 7,745,460 | ⤷ Subscribe |
| Bausch And Lomb Inc | BEPREVE | bepotastine besilate | SOLUTION/DROPS;OPHTHALMIC | 022288-001 | Sep 8, 2009 | 8,877,168 | ⤷ Subscribe |
| Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | 6,051,698 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BAUSCH AND LOMB INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Ophthalmic Solution | 1.5% | ➤ Subscribe | 2013-09-09 |
International Patents for BAUSCH AND LOMB INC Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 102157608 | ⤷ Subscribe |
| China | 1902195 | ⤷ Subscribe |
| World Intellectual Property Organization (WIPO) | 2012142372 | ⤷ Subscribe |
| Mexico | 2020001602 | ⤷ Subscribe |
| Canada | 2890471 | ⤷ Subscribe |
| World Intellectual Property Organization (WIPO) | 2007131050 | ⤷ Subscribe |
| European Patent Office | 4342537 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for BAUSCH AND LOMB INC Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3043773 | 21C1057 | France | ⤷ Subscribe | PRODUCT NAME: MOMETASONE OU L'UN DE SES SELS AVEC OLOPATADINE OU L'UN DE SES SELS; NAT. REGISTRATION NO/DATE: NL52121 20211026; FIRST REGISTRATION: AT - 140638 20210426 |
| 2826776 | LUC00207 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: A COMBINATION OF (A) (R)-1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND (B) N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/18/1306 20181106 |
| 2826776 | 301105 | Netherlands | ⤷ Subscribe | PRODUCT NAME: EEN COMBINATIE VAN (A) (R)-1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUOR-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPAANCARBOXAMIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN (B) N-(5-HYDROXY-2,4-DITERT-BUTYL-FENYL)-4-OXO-1H-CHINOLINE-3-CARBOXAMIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/18/1306 20181106 |
| 1631293 | 14C0056 | France | ⤷ Subscribe | PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225 |
| 2826776 | CA 2021 00013 | Denmark | ⤷ Subscribe | PRODUCT NAME: A COMBINATION OF (A) (R)-1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND (B) ....; REG. NO/DATE: EU/1/18/1306 20181106 |
| 1631293 | 2014C/042 | Belgium | ⤷ Subscribe | PRODUCT NAME: MIRVASO (BRIMONIDINE) EN FARMACEUTISCHE ZOUTEN DAARVAN VOOR GEBRUIK ALS MEDICIJN VOOR HET BEHANDELEN VAN ROSACEA GEINDUCEERDE ROODHEID; AUTHORISATION NUMBER AND DATE: EU/1/13/904 20140221 |
| 0957929 | SPC/GB06/021 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
